Beone Medicines Ltd.

ONC · Nasdaq · ·

比較

$415.95-1.0%11月12日終値

2026年9月30日までの数値（2026年11月5日提出の10-Qより）

1W: +2.2%
1M: +18.3%
3M

Beone Medicines Ltd.（ONC）株——良い事業でしょうか？ — InspectStocks

Beone Medicines Ltd.

ONC · Nasdaq · ·

比較

$415.95-1.0%11月12日終値

2026年9月30日までの数値（2026年11月5日提出の10-Qより）

1W: +2.2%
1M: +18.3%
3M

Just reported

Q3 2026 results

From Beone Medicines's results release of 2026年11月5日; its quarterly report has since been filed.

Revenue
Actual
$1.89B
+34% y/y
+11% q/q
Guided
—
No guide given
EPS, GAAP
Actual
$3.25
+213% y/y
+56% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
$418.7M
+157% y/y
+29% q/q
Guided
—
No guide given

Company outlook

Full year 2026

Revenue$6.9B – $7B+30% y/y First given
Operating income, adjusted$1.9B – $2BFirst given
Operating income, GAAP$1.2B – $1.3B+180% y/y First given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Beone Medicines is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

All 355 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

どうやって稼いでいるか

Sales of cancer medicines98%

売上構成比はQ1 2026の推計であり、提出された報告書の数字ではありません。

競合

何を売っているか6

BRUKINSA (zanubrutinib)
A pill for several blood cancers that blocks Bruton tyrosine kinase, a protein that helps certain cancer cells grow.
TEVIMBRA (tislelizumab)
An antibody treatment that blocks a signal cancer cells use to reduce the immune system's attack on them.
BEQALZI (sonrotoclax)
A pill that blocks the B-cell lymphoma 2 protein, which can help cancer cells survive; it is approved in the United States for certain mantle cell lymphoma patients.

さらに3件を表示

XGEVA (denosumab)
An antibody medicine marketed by BeOne in China to help prevent bone complications in people with cancer and to treat giant cell tumor of bone.
BLINCYTO (blinatumomab)
A medicine marketed by BeOne in China for acute lymphoblastic leukemia that helps immune cells recognize and attack cancer cells.
KYPROLIS (carfilzomib)
A medicine marketed by BeOne in China for multiple myeloma that interferes with a process cancer cells use to dispose of unwanted proteins.

誰が買っているか2

Commercial distributors and other medicine buyers purchase BeOne's products for sale or supply to treatment providers.
Government health systems and private insurers decide which medicines they cover and reimburse; patients receive the medicines through their cancer care.

何に支えられ、何に崩されうるか

事業が頼っているもの

1A large share of sales comes from BRUKINSA, so its continued use by doctors and patients and its coverage by health systems and insurers matter to revenue.
2Sales depend on government and private reimbursement, including coverage decisions and negotiated medicine prices in China and other markets.
3For licensed medicines such as XGEVA, BLINCYTO and KYPROLIS, BeOne depends on partner agreements and partner or contract manufacturers for supply.
4BeOne relies on some outside manufacturers, suppliers and research contractors for medicines, materials and development work.

うまくいかなくなる可能性

1Clinical trials may not show that medicines work or are safe enough for regulators to approve them; delays, trial failures or safety problems could prevent new medicines or uses from reaching patients.
2Competition from medicines such as IMBRUVICA, CALQUENCE and KEYTRUDA, along with changes in coverage, reimbursement or medicine pricing, could reduce sales or patient access.
3BeOne operates across China, the United States and other markets, so changes in government policy, regulation or trade relations can affect approvals, manufacturing, sales and the movement of money.

財務諸表をすべて見る →

Beone Medicines Ltd.について

BeOne Medicines discovers, develops, makes and sells treatments for cancer. Its main medicine, BRUKINSA (zanubrutinib), is a pill that blocks Bruton tyrosine kinase, a protein involved in some blood cancers. It also sells TEVIMBRA, an antibody that blocks a signal cancers use to dampen immune attacks, and markets licensed cancer medicines in China.

本社: Basel, Switzerland
設立: 2010
従業員数: More than 12,000 (Q2 2026, medium)
上場市場: Nasdaq
決算期: December 31

Beone Medicines Ltd. 自身が米国証券取引委員会（SEC）に提出した書類にもとづきます。数字は報告されたままで、1 株当たりの履歴は今日の株数基準に修正済みです。これは事業の説明です——投資助言ではなく、売買を勧めるものでもありません。

Just reported